Commit Biologics has developed a novel platform technology to harness the power of the complement system, a vital part of the innate immune system, with the potential to create a new type of treatment for a variety of cancers and autoimmune diseases.

Commit Biologics

Commit Biologics (Commit) is a pioneer in activating the complement system to kill specific target cells, with applications in cancers and autoimmune diseases. Spun out of Aarhus University, and building on more than three decades of research, Commit’s Bispecific Complement Engaging (BiCE™) platform can supercharge a conventional monoclonal antibody to activate the complement system more effectively. This is achieved by combining single domain antibodies that engage C1q, the starting point for the complement activation cascade, with an antibody that binds to a cellular target.  The modular approach of the BiCE™ technology can be used to develop therapeutics across multiple tumor-associated antigens and immune cell targets. Complement is a largely untapped aspect of the body’s natural immune system that leverages both the direct cytolytic activity of complement along with its ability to bridge recruitment and activation of both innate and adaptive immune cells – a new approach to killing cells which can be used in combination or on a standalone basis. Commit is backed by major investors including Bioqube Ventures and Novo Holdings, as well as initial funding from the Bio Innovation Institute from Denmark.

BioInnovation Institute

Today, Commit Biologics officially launches with a €16m seed financing round from leading life sciences investors Bioqube Ventures and Novo Holdings.
 
As a pioneer in the activation of the complement system, Commit Biologics will use this financing to accelerate the development of its Bispecific Complement Engaging (BiCE™) platform to treat #cancer and #autoimmune disease. 
 
Our proprietary platform uses single domain #antibodies that bind to the complement protein C1q to activate the complement system, a fast-acting and potent part of the innate #immunesystem.
 
If you would like to learn more about our approach to activating the complement system, see the full press release on our website https://commitbio.com/ or get in touch!
 
#ComplementSystem #CommitBiologics

Our CEO, Krishna Polu, was interviewed by Optimum Strategic Communications for the latest episode of #OptimumTV.
 
In his conversation with Stephen Adams, Krishna highlighted Commit Biologics' innovative #BiCEtechnology, which supercharges conventional #antibodies with complement engagers to harness the complement system's powerful ability to fight #cancer and #autoimmune diseases.
 
Having recently emerged from stealth with €16 million in seed financing from top investors Bioqube Ventures and Novo Holdings, Krishna discussed how their invaluable support will help Commit achieve key milestones over the next 12 to 18 months.
 
Watch Krishna's episode of Optimum TV below!
 
#ComplementSystem #ImmuneSystem

This week, our CSO, Nick Stub Laursen, will be attending the 16th International Conference on Complement Therapeutics in Loutraki, Ancient Corinth, Greece. 
 
Nick will be delivering a poster presentation on new data from Commit Biologics innovative BiCE platform which will show that Commit’s second generation #BiCE™ molecules induce superior complement-mediated cell killing compared to other technologies.
 
With a novel mechanism of action, Commit’s technology has the potential to be developed into best-in-class therapeutics for the treatment of cancer and autoimmune diseases.
 
To read more on the presentation, read the press release in the comments below!
 
#ComplementSystem #ImmuneSystem #Antibodies

Happy to announce that Commit Biologics has received an Innobooster Grant of 5M DKK from the Innovation Fund Denmark (IFD) to support further development of the BiCE technology to fight cancer. We are grateful for the support from #IFD.

Our CDO, Pascal Merchiers and Scientist, Laust Bavnhøj, are at the Antibody Engineering & Therapeutics Europe Conference in London this week. 
 
If you are attending and would like to find out about Commit Biologics' BiCE™ Technology Platform and how it can supercharge a conventional monoclonal #antibody to activate the #ComplementSystem, please reach out.
 
To learn more, visit our website through the link in our comments below.
 
#AntibodyEngineeringandTherapeuticsEurope2024 #ImmuneResponse #ImmuneSystem #BiCEtechnology

COM:COMMITBIO

Commit Biologics

Financials Not Available